Why the study?
Does ertugliflozin alter the association between interval cardiovascular events and kidney outcomes compared to placebo?
Population
Participants from the VERTIS CV trial (people after and without an interval cardiovascular event)
Comparison
Ertugliflozin vs Placebo
Design
Cohort
Key result
The abstract outlines a post-hoc analysis of the VERTIS CV trial assessing the effect of ertugliflozin versus placebo on kidney outcomes after interval cardiovascular events, but reports no results.
Authors
Loading...
No results reported on ertugliflozin's kidney effects after interval CV events; leaves open whether SGLT2 inhibition modifies this association.
RCT
Does ertugliflozin alter the association between interval cardiovascular events and kidney outcomes compared to placebo?
Odutayo et al. (2026) conducted an RCT in Cardiovascular events and kidney disease. Ertugliflozin vs. Placebo was evaluated on Kidney outcomes after interval cardiovascular events. The abstract outlines a post-hoc analysis of the VERTIS CV trial assessing the effect of ertugliflozin versus placebo on kidney outcomes after interval cardiovascular events, but reports no results.